Arvinas (NASDAQ:ARVN – Get Free Report) and uniQure (NASDAQ:QURE – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Institutional & Insider Ownership
95.2% of Arvinas shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 7.3% of Arvinas shares are owned by company insiders. Comparatively, 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Arvinas has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, uniQure has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.
Profitability
This table compares Arvinas and uniQure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arvinas | 2.94% | 1.91% | 1.29% |
| uniQure | -1,350.73% | -111.96% | -29.01% |
Analyst Recommendations
This is a summary of current ratings and price targets for Arvinas and uniQure, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arvinas | 1 | 2 | 5 | 1 | 2.67 |
| uniQure | 1 | 3 | 12 | 1 | 2.76 |
Arvinas presently has a consensus price target of $15.40, indicating a potential upside of 110.96%. uniQure has a consensus price target of $53.25, indicating a potential upside of 137.41%. Given uniQure’s stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Arvinas.
Earnings and Valuation
This table compares Arvinas and uniQure”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arvinas | $262.60 million | 1.79 | -$80.80 million | $0.10 | 73.00 |
| uniQure | $18.67 million | 83.33 | -$198.97 million | ($4.01) | -5.59 |
Arvinas has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Summary
Arvinas beats uniQure on 10 of the 14 factors compared between the two stocks.
About Arvinas
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.
